Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Beta-cell recovery to counter diabetes

Objectif

Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g. following a strict diet) reducing patient QoL. Even with insulin, less than 20% of patients achieve their target glucose level, which eventually leads to vascular complications (e.g. stroke, renal disease) reducing life expectancy by 10-15 years.
DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels increases.
We expect to out-license our drug to a pharma company, some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026 with the proceeds from Series A to be raised in 2023, which is 80% secured.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-EIC-2023-ACCELERATOR-01

Voir tous les projets financés au titre de cet appel

Coordinateur

DIOGENX SAS
Contribution nette de l'UE
€ 2 500 000,00
Adresse
180 AVENUE DU PRADO
13008 Marseille
France
PME
Oui
Région
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 5 673 000,00